Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2

• Published in: The Journal of clinical investigation Vol. 132; no. 24; pp. 1 - 16
• Main Authors: Shi, Guoli, Chiramel, Abhilash I., Li, Tiansheng, Lai, Kin Kui, Kenney, Adam D., Zani, Ashley, Eddy, Adrian C., Majdoul, Saliha, Zhang, Lizhi, Dempsey, Tirhas, Beare, Paul A., Kar, Swagata, Yewdell, Jonathan W., Best, Sonja M., Yount, Jacob S., Compton, Alex A.
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 15.12.2022
• Subjects: Adaptive immunity; Animal models; Antiviral drugs; Autoimmune diseases; Autoimmunity; Biomedical research; Cancer; Care and treatment; Cell culture; Cell growth; Coronaviruses; COVID-19; Disease transmission; Host-virus relationships; Humans; Immune response; Immunity, Innate; Immunocompromised host; Infections; Influenza; Inhibitor drugs; Kinases; Membrane Proteins; MTOR Inhibitors; Nuclear transport; Phosphorylation; Proteins; Rapamycin; RNA-Binding Proteins; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sirolimus - pharmacology; Targeted cancer therapy; Testing; Tissue culture; TOR protein; Viral diseases; Viral infections; Virus Internalization; Viruses; United States; COVID-19; Lysosomes; Innate immunity; Autophagy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in immunocompromised individuals is associated with prolonged virus shedding and evolution of viral variants. Rapamycin and its analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA approved as mTOR in...